Altered γ-Secretase Processing of APP Disrupts Lysosome and Autophagosome Function in Monogenic Alzheimer's Disease by Hung, COY & Livesey, FJ
ArticleAltered g-Secretase Processing of APP Disrupts
Lysosome and Autophagosome Function in
Monogenic Alzheimer’s DiseaseGraphical AbstractHighlightsd APP and PSEN1 mutant neurons have deficits in lysosome
proteolysis
d BACE1 inhibition rescues lysosome and autophagy defects
d PSEN1mutant phenotypes are rescued by genetic deletion of
APP
d Lysosome and autophagy defects are causes of neuronal
dysfunction in ADHung & Livesey, 2018, Cell Reports 25, 3647–3660
December 26, 2018 ª 2018 The Authors.
https://doi.org/10.1016/j.celrep.2018.11.095Authors
Christy O.Y. Hung, Frederick J. Livesey
Correspondence
r.livesey@ucl.ac.uk
In Brief
Hung and Livesey demonstrate that
mutations in APP and PSEN1 that are
causal for early onset Alzheimer’s disease
lead to major defects in lysosome
function and autophagy in human
neurons. The rapid appearance of these
defects indicates that they are causes,
rather than consequences, of neuronal
dysfunction in Alzheimer’s disease.
Cell Reports
ArticleAltered g-Secretase Processing of APP
Disrupts Lysosome and Autophagosome Function
in Monogenic Alzheimer’s Disease
Christy O.Y. Hung1 and Frederick J. Livesey1,2,3,*
1Gurdon Institute and ARUK Stem Cell Research Centre, University of Cambridge, Cambridge CB2 1QN, UK
2UCL Great Ormond Street Institute of Child Health, Guildford Street, London WC1N 1EH, UK
3Lead Contact
*Correspondence: r.livesey@ucl.ac.uk
https://doi.org/10.1016/j.celrep.2018.11.095SUMMARY
Abnormalities of the endolysosomal and autophagy
systems are found in Alzheimer’s disease, but it is
not clear whether defects in these systems are a
cause or consequence of degenerative processes
in the disease. In human neuronal models of mono-
genic Alzheimer’s disease, APP and PSEN1 muta-
tions disrupt lysosome function and autophagy,
leading to impaired lysosomal proteolysis and defec-
tive autophagosome clearance. Processing of APP
by g-secretase is central to the pathogenic changes
in the lysosome-autophagy system caused by
PSEN1 and APP mutations: reducing production of
C-terminal APP by inhibition of BACE1 rescued these
phenotypes in bothAPP andPSEN1mutant neurons,
whereas inhibition of g-secretase induced lysosomal
and autophagic pathology in healthy neurons. Defects
in lysosomes and autophagy due to PSEN1 muta-
tions are rescued by CRISPR-knockout of APP.
These data demonstrate a key role for proteolysis
of the C-terminal of APP by g-secretase in neuronal
dysfunction in monogenic Alzheimer’s disease.
INTRODUCTION
Abnormalities of the endolysosomal and autophagy systems are
both found in Alzheimer’s disease (AD) (Nixon, 2017; Lie and
Nixon, 2018). Prominent enlargement of endosomal compart-
ments precedes the appearance of neurofibrillary tangles and
neuritic plaques in mouse models of AD (Cataldo et al., 2000).
Similarly, selective accumulation of lysosomal dense bodies
and autophagic vacuoles in dystrophic neurites has been
observed in post-mortem brain samples of people with AD
(Nixon et al., 2005), suggesting that autolysosomal proteolysis
is impaired in AD (Nixon, 2017). Genome-wide association
studies have identified SNPs in several genes with roles in the
endolysosomal and autophagy systems as impacting disease
risk, including PICALM, CLU, SORL1, ABCA7, and BIN1 (Karch
and Goate, 2015). These underscore the significance of the
endolysosomal and autophagy systems as a genetic risk hotspot
in AD (Nixon, 2017). However, it is not clear whether defects inCell Repo
This is an open access article undlysosomal and autophagic systems are a cause or consequence
of degenerative processes in AD.
Collectively, genetic data place APP processing by g-secre-
tase as central to disease initiation in monogenic forms of AD,
including familial AD due to PSEN1 and APP mutations (Selkoe,
2002). The majority of known familial AD mutations are auto-
somal dominant and affect the amyloid precursor protein (APP)
gene or the catalytic components of the g-secretase APP-
processing complex, presenilin (PSEN) 1 and 2 (Bertram and
Tanzi, 2008). As well as missense mutations, increased APP
gene dosage due either to trisomy of chromosome 21 (Ts21) or
duplication of the APP locus (APP (dup)) also leads to early onset
AD (Rovelet-Lecrux et al., 2006). Conversely, a protective muta-
tion near the BACE-cleavage site in APP has been identified that
reduces the risk of developing dementia (Jonsson et al., 2012).
How changes in APP processing by g-secretase lead to AD is
still not well understood. Deposition of amyloid beta (Ab) peptide
fragments of the amyloid precursor protein (APP) in amyloid
plaques and hyperphosphorylated tau in neurofibrillary tangles
are the cellular hallmarks of AD (O’Brien and Wong, 2011). The
amyloid hypothesis proposes that it is the accumulation of
extracellular toxic forms of Ab as both soluble oligomers and
insoluble plaques that is the primary pathologic driver of the
disease (Hardy and Selkoe, 2002). However, causal links be-
tween production of potentially toxic longer forms of Ab pep-
tides, amyloid deposition, and disease initiation have not been
definitively demonstrated and remain contentious (De Strooper
and Karran, 2016).
Nascent APP proteins mature through the constitutive secre-
tory pathway from endoplasmic reticulum and the Golgi appa-
ratus and are transported to the plasma membrane (Thinakaran
and Koo, 2008). Endosomal and lysosomal compartments are
involved in APP processing and perturbation of the endolysoso-
mal system can lead to altered APP processing, Ab peptide pro-
duction and amyloid accumulation (Nixon, 2017). Conversely,
increased expression of APP or expression of mutant APP in
fibroblasts leads to dysfunction of the endolysosomal system
(Cataldo et al., 2008). AD mutations in PSEN1 lead to altered
lysosomal function, including reduced acidification through
altered PSEN1-mediated recruitment of the Vo ATPase to the
lysosome, which in turns leads to defects in neuronal macroau-
tophagy (Lee et al., 2010). Moreover, PSEN1 deficiency has been
shown to alter lysosomal calcium storage and release (Coen
et al., 2012; Neely Kayala et al., 2012). While the appearancerts 25, 3647–3660, December 26, 2018 ª 2018 The Authors. 3647
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of pathological changes in the endolysosomal and autophagy
systems is an important early feature of AD, whether these
changes are causes or consequences of primary drivers of
neurodegenerative processes remain unclear (Peric and An-
naert, 2015).
To address this question, we investigated howADmutations in
APP and PSEN1 affect the endolysosomal and autophagy sys-
tems in human-stem-cell-derived cortical neurons. We and
others have previously shown that mutations in APP and
PSEN1 lead to immediate changes in APP processing, with
either increased relative or absolute amounts of longer forms
of Ab peptides (Yagi et al., 2011; Muratore et al., 2014; Moore
et al., 2015). We now find that mutations in both APP and
PSEN1 causal for monogenic, early onset AD, lead to major de-
fects in lysosome function and autophagy in induced pluripotent
stem cell (iPSC)-derived human neurons, with APP mutations
also disrupting endosomal function. Reducing production of
C-terminal APP by inhibition of BACE1 rescued these pheno-
types in both APP and PSEN1 mutant neurons, and defects in
the lysosomal and autophagic systems due to PSEN1mutations
are prevented by CRISPR knockout of APP. These data demon-
strate that compromised proteolysis of the C-terminal of APP by
g-secretase by autosomal dominant mutations in both PSEN1
and APP causes dysfunction of the endolysosomal and auto-
phagy systems in human neurons and is a driver of neurodegen-
eration in familial AD.
RESULTS
AD Mutations in APP, but Not PSEN1, Result in Early
Endosome Abnormalities in Human Cortical Neurons
To study the effects of AD mutations in APP and PSEN1 on the
neuronal endolysosomal system, we generated cortical excit-
atory neurons from iPSCs derived from individuals with genetic
changes or mutations causal for AD: APP V717I, trisomy chro-
mosome 21 (Ts21), APP duplication (APPdup), and three
different PSEN1 mutations (Y115C, M146I, and Intron 4). Neu-
rons were generated according to our previously described
methods (Shi et al., 2012a) and confirmed as being cortical in
neuronal identity by both gene expression and immunofluores-
cence (Figures S1A–S1C). As we previously described (Moore
et al., 2015), both PSEN1 and APPmissense mutations increase
the proportion of longer forms of Ab relative to shorter forms, as
reflected in reduced Ab40:Ab42 ratios, whereas APPdup and
Ts21 neurons overproduce all measured forms of Ab peptides
(Figures S1D–S1G).
Endosomes are highly active processing sites for APP, and
accumulation of enlarged early endosomes and lysosomes in
neurons has been observed in post-mortem brain samples of pa-
tients with sporadic AD and some forms of familial AD (Cataldo
et al., 2000, 2001; Colacurcio et al., 2018; Nixon, 2017). Using
a GFP fusion of the small Rab GTPase Rab5A to visualize early
endosomes, we observed significantly enlarged Rab5A-positive
early endosomes in neurons with missense mutations in APP or
increased copy number of APP (APPdup and Ts21), compared
with those in control neurons (Figures 1A and 1B). Moreover,
the number of enlarged early endosomes per neuron was
increased significantly in both APP duplication and missense3648 Cell Reports 25, 3647–3660, December 26, 2018mutation neurons (Figure 1C). This was accompanied by upregu-
lation of the total mass of early endosomes, as reflected in an in-
crease in endogenous Rab5A protein levels (Figures 1D and 1E).
In contrast, endosomal number and size, as measured by
imaging and western blot levels of Rab5, were unchanged in
neurons with each of three PSEN1 mutations (M146I, Y115C,
and Intron 4). However, levels of the lysosomal protein LAMP1
were increased in both APP and PSEN1 Y115C or M146I mutant
neurons (Figures 1D and 1F), indicating that both classes of mu-
tations share defects in late endosomes and/or lysosomes.
Accumulation of Enlarged Late Endosomes and
Lysosomes in Human Neurons with PSEN1 or APP
Mutations
To further investigate potential defects in the lysosomal system,
we studied late endosomes and/or lysosomes in human cortical
neurons with mutations in APP and PSEN1 by live imaging. The
number and size of lysosomes was increased in monogenic AD
neurons of each genotype (APP and PSEN1 mutations, Ts21),
with the exception of PSEN1 Intron 4 neurons (Figures 2A–2C).
Neurons with APP or PSEN1 mutations had accumulations of
clustered lysosomes in their cell bodies (Figure 2A). In addition,
the average size (area) of lysosomes in APP and PSEN1 mutant
neurons was significantly larger than that of control neurons (Fig-
ure 2B). This difference in average lysosome size was due to a
change in the distribution of lysosome sizes within mutant neu-
rons, whereby mutant neurons contained a population of very
large lysosomes, together with a set of lysosomes of the same
size as those in control neurons (Figure 2B). To confirm that
LAMP1 expression does not alter lysosome size, we examined
the size of LAMP1+ vesicles by either expression of RFP-tagged
LAMP1 (live cell) or immunostaining for endogenous LAMP1
(fixed cell) in control neurons. We observed a very similar size
distribution profile using either method (Figures S2A and S2B).
Furthermore, we analyzed the size of endogenous LAMP1+ ves-
icles in control and APP V717I neurons. Consistent with our data
using RFP-tagged LAMP1, we observed a significant increase in
the size of endogenous LAMP1 in APP mutant neurons
compared with control (Figures S2C and S2D).
The lack of detectable differences in lysosomal biology at this
early stage in PSEN1 Intron4 neurons is surprising, given that
these neurons have similar changes in Ab peptide production
as the other PSEN1 mutant neurons (Figure S1). However, the
molecular nature of the PSEN1 Intron4 mutation is qualitatively
different from the majority of PSEN1 mutations, which are
missense protein-coding mutations that result in single amino
acid substitutions (De Jonghe et al., 1999), and may enable
some degree of compensation by the more abundant wild-type
form of PSEN1 at these stages in relatively young neurons.
Impaired Axonal Lysosome Transport and Proteolysis
Deficits in Human APP and PSEN1 Mutant Neurons
Given the accumulation of abnormally large lysosomes in the cell
bodies of APP and PSEN1mutant neurons, wemeasured axonal
transport of lysosomes in human familial AD neurons and con-
trols. Axonal trafficking of lysosomes was quantified using
time-lapse microscopy of axons in a microfluidic device, with
lysosomes labeled with a fluorescent dye that preferentially
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Figure 1. Alzheimer’s Disease Mutations in APP, but Not PSEN1, Result in Early Endosome Abnormalities in Human Cortical Neurons
(A) Representative images of neurons generated from three independent non-demented controls, APP (dup), Ts21, and APP V717I and PSEN1mutants (Y115C,
M146I, or Intron 4) induced pluripotent stem cells (iPSCs). Scale bar, 10 mm.
(B and C) Significant increases in the size (B) and number per unit area (C) of Rab5A-GFP positive endosomes in APP but not PSEN1mutant neurons, compared
with non-demented controls (one-way ANOVAwith Tukey correction between controls and Alzheimer’s Disease [AD] neurons in each case). Rab5A-GFP+ vesicle
size measures in (B) were from three independent experiments, including an independent neural induction in each case. Total number of vesicles measured (n):
260 (Control 1), 654 (Control 2), 265 (Control 3), 472 (APP V717I), 574 (APPdup), 700 (Ts21), 250 (PSEN1 Intron4), 355 (PSEN1 Y115C), and 620 (PSEN1M146I).
Number of vesicles per unit cytoplasmic area (C) was measured in three independent experiments (n = 3), with total numbers of cells indicated within each bar.
(D–F) Representative western blots of Rab5A, LAMP1, and neuron-specific b3-tubulin in three independent control and AD neurons are shown (D). Levels of
Rab5A (E) and LAMP1 (F) were calculated relative to b3-tubulin from three independent experiments (n = 3), including an independent neural induction in each
case. Error bars, SEM.
See also Figure S1.identifies acidic organelles (LysoTracker). We observed that
LysoTracker-positive vesicles were concentrated near the
somatodendritic region (Figure S3). Furthermore, to prove that
LysoTracker-positive structures are functional lysosomes, we
treated LysoTracker-stained neurons with glycyl-L-phenylala-
nine-b-naphthylamide (GPN), which is a substrate of lysosomal
protease cathepsin C that triggers osmotic lysis of lysosomes
after cleavage. We observed that cleavage of GPN by cathepsin
C diminished fluorescence of LysoTracker-positive organelles,
confirming that they are lysosomes (Figure S4). For this and
subsequent analyses, the PSEN1 Intron4 mutation was not
included, given the lack of endosome, lysosome, and autophagy
phenotypes.
Consistent with previous reports of similar assays (Hung and
Coleman, 2016), lysosomal movements were observed in both
anterograde and retrograde directions in these neurons (Fig-ure 3A). Moreover, the average size of axonal lysosomes was
significantly increased in APP or PSEN1 (M146I and Y115C)
mutant neurons (Figure 3B). Analyses of the rates of lysosomal
transport revealed that APP or PSEN1 (M146I and Y115C) muta-
tions reduced the numbers of moving lysosomes (Figure 3C).
Furthermore, this reduction was seen in both anterograde and
retrograde directions (Figure 3C).
Lysosomes accumulating within the distal ends of swollen
axons in mouse models of AD contained low levels of multiple
luminal lysosomal proteases (Gowrishankar et al., 2015),
including cathepsin D (CatD). To investigate CatD activation
within lysosomes in control and monogenic AD neurons, we
live-imaged axons co-labeled with LysoTracker and BODIPY-
FL-pepstatin A, which binds selectively to active CatD (Chen
et al., 2000). To analyze the extent of co-migration between lyso-
somes and activatedCatD, kymographswere generated for eachCell Reports 25, 3647–3660, December 26, 2018 3649
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Figure 2. Accumulation of Enlarged Late Endosomes and Lysosomes in Human Neurons with PSEN1 or APP Mutations
(A) Representative images of neurons expressing a LAMP1-RFP fusion protein (red; blue, nuclei labeled with NucBlue). Scale bar, 10 mm.
(B and C) Significant increases in the size (B) and number per unit area (C) of LAMP1-RFP-positive late endosomes and/or lysosomes in APP and PSEN1mutant
(Y115C, M146I) neurons, but not PSEN1 Intron 4 neurons, compared with non-demented controls (one-way ANOVA with Tukey correction between controls and
AD neurons in each case). LAMP1-RFP+ vesicle size measures in (B) were from three independent experiments, including an independent neural induction in
each case. Total number of vesiclesmeasured (n): 484 (Control 1), 341 (Control 2), 50 (Control 3), 199 (APP V717I), 561 (APPdup), 579 (Ts21), 187 (PSEN1 Intron4),
321 (PSEN1 Y115C), 358 (PSEN1 M146I). Number of vesicles per unit cytoplasmic area (C) was measured in three independent experiments (n = 3), with total
numbers of cells indicated within each bar. Error bars, SEM.
See also Figure S2.channel (GFP andRFP) and for their overlays (Figure 3D).We then
quantified the extent of co-migration in the axon by comparing
pairs of kymographs generated for each channel (Figure 3E). In
control neurons, over 60% of the lysosomes contained activated
CatD (Figure 3E). However, fewer than 40% of the lysosomes in
monogenic AD neurons contained activated CatD (Figure 3E).
Defective Degradation of Autophagosomes in Human
APP and PSEN1Mutant Neurons
Impaired lysosomal clearance can be associated with additional
changes in autophagy, including accumulation of autophagic
vesicles (Lie and Nixon, 2018). Therefore, we carried out a num-
ber of studies of autophagy in human familial AD neurons. To
assess autophagosome size, we expressed an RFP-fusion of
the autophagy receptor p62/SQSTM1 in neurons of each geno-
type and measured the size of p62/SQSTM1-positive autopha-
gic vesicles in control and monogenic AD neurons (Figure 4A).
We observed a striking accumulation of enlarged p62-positive
autophagosomes in both APP and PSEN1 mutant neurons
compared to control neurons, indicating impairment in auto-
phagy (Figures 4A and 4B).
Given the dynamic natureof autophagy,wemeasured autopha-
gic flux in control and monogenic AD neurons to quantify
autophagosome synthesis and degradation, using a previously re-
portedquantitative approach (Figure 4C) (Rubinsztein et al., 2009).
To do so, we treated neurons with the mitochondrial respiratory
chain uncoupler (CCCP) to activate autophagy by triggering the3650 Cell Reports 25, 3647–3660, December 26, 2018loss of mitochondrial membrane potential (Figure 4C). The degra-
dative phase of autophagy was blocked by v-ATPase inhibition
with bafilomycin A1 (Baf A1) in either the presence or absence of
autophagy induction by CCCP (Figure 4C). Western blot analysis
of the relative amounts of LC3-I and LC3-II among the different
conditions (with and without CCCP, with and without Baf A1)
enabled the measurement of both the synthetic and degradative
phases of autophagy (Figure 4C) (Rubinsztein et al., 2009).
Autophagy was induced in both control and monogenic AD
neurons by CCCP treatment, as demonstrated by significant
upregulation of LC3-II in the presence of CCCP and Baf A1
compared with neurons treated with Baf A1 alone (Figure 4D).
However, comparing neurons treated with CCCP to induce auto-
phagy with those treated with CCCP and Baf A1 (blocking auto-
phagosome degradation) found a further elevation of LC3-II
levels only in control neurons but not in the different AD neurons,
indicating an impairment of autophagosome degradation in
monogenic AD neurons (Figures 4D and 4E).
We confirmed that the degradative phase of autophagy is
compromised in familial AD neurons using an alternative mTOR-
independent autophagy inducer, the Akt inhibitor 10-(40-(N-dieth-
ylamino) butyl)-2-chlorophenoxazine hydrochloride (10-NCP)
(Tsvetkov et al., 2010). As seenwith autophagy induction bymito-
chondrial stress with CCCP, autophagy induction with 10-NCP
followed by inhibition of the vATPase with Baf A1 did not result
in a further increase in LC3-II levels in familial neurons (Figures
4D and 4F). As with CCCP-induced autophagy, familial AD
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Figure 3. Impaired Axonal Lysosome Transport and Proteolysis Deficits in Human APP and PSEN1 Mutant Neurons
(A) Representative kymographs showing transport of lysosomes labeled with LysoTracker Red DND 99. Scale bar, 10 mm.
(B) Significant increase in the average size of axonal lysosome in both APP and PSEN1 mutant (Y115C, M146I) neurons, compared with non-demented control
(one-way ANOVA with Tukey correction between control and AD neurons in each case). Total number of axons measured (n): 35 (Control), 32 (APP V717I),
25 (APPdup), 45 (Ts21), 33 (PSEN1 Y115C), and 28 (PSEN1 M146I). Error bars, SEM.
(C) Significant reduction in lysosome motility in both anterograde and retrograde directions in both APP and PSEN1 mutant neurons, compared with controls
(one-way ANOVA with Tukey correction between controls and AD neurons in each case). Total number of axons measured (n): 35 (Control 1), 32 (Control 2),
32 (APP V717I), 25 (APPdup), 45 (Ts21), 33 (PSEN1 Y115C), and 28 (PSEN1 M146I). Error bars, SEM.
(D) Proteolysis deficits in both APP and PSEN1 mutant (Y115C, M146I) neurons, as detected by live imaging of iPSC-derived cortical neurons co-labeled with
100 nM LysoTracker Red DND-99 and BODIPY-FL-pepstatinA. Scale bar, 10 mm.
(E) Significant reduction in the percentage of lysosomes that contained CatD-positive signals in bothAPP and PSEN1mutant (Y115C, M146I) neurons, compared
with non-demented controls (one-way ANOVAwith Tukey correction between controls and AD neurons in each case). Axonsweremeasured in three independent
experiments, with total numbers of axons (n) indicated within each bar. Error bars, SEM.
See also Figures S3 and S4.neurons demonstrated defective autophagy degradation when
autophagy was induced by Akt inhibition (Figures 4D and 4F).
Gamma-Secretase Inhibition Disrupts Function of the
Lysosomal-Autophagic System in Human Neurons
Previous studies have suggested that intraneuronal accumulation
of the C terminus of APP (APP-CTF) is a consequence of impairedlysosomal-autophagic degradation, rather than a cause of lyso-
some or autophagy dysfunction (Peric and Annaert, 2015).
Processing of APP by BACE1 in the endosome generates the
99 amino acid C-terminal fragment of APP (b-CTF), which is in
turn a substrate for g-secretase in the lysosome.
We observed a significant increase in APP-b-CTF levels in both
APP and PSEN1 mutant neurons compared to control neuronsCell Reports 25, 3647–3660, December 26, 2018 3651
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Figure 4. Defective Degradation of Autophagosomes in Human APP and PSEN1 Mutant Neurons
(A) Increased size of autophagosomes in human cortical excitatory neurons withAPP and PSEN1mutations, as detected by live imaging of iPSC-derived neurons
co-expressing p62-RFP (red) and a LC3-GFP (green) fusion proteins (blue, nuclei labeled with NucBlue). Scale bar, 10 mm.
(B) Significant increases in the size of p62-RFP-positive autophagosomes in both APP and PSEN1 mutant (Y115C, M146I) neurons, compared with non-
demented controls (one-way ANOVA with Tukey correction between controls and AD neurons in each case). p62-RFP+ vesicle size measures in (B) were from
three independent experiments, including an independent neural induction in each case. Total number of vesicles measured (n): 324 (Control 1), 183 (Control 2),
448 (Control 3), 376 (APP V717I), 355 (APPdup) (1), 350 (APPdup) (2), 372 (Ts21), 225 (PSEN1 Y115C), and 399 (PSEN1 M146I). Error bars, SEM.
(C) Diagram of the autophagy flux assay. Autophagic degradation was calculated by comparing LC3-II levels following treatment with autophagy activators
(CCCP or 10-NCP) in the presence (lane 4) or absence (lane 3) of bafilomycin A1 (i.e., lane 4 versus lane 3).
(D–F) Autophagosome degradation was significantly reduced in bothAPP andPSEN1mutant (Y115C orM146I) neurons, compared with non-demented controls,
as calculated from the western blot analysis (two-tailed t test between controls and AD neurons). Representative western blots of LC3I/II and neuron-specific
b3-tubulin from neurons derived from three independent non-demented controls and monogenic AD iPSCs are shown (D). Autophagosome degradation
following autophagy induction with either CCCP (20 mM) (E) or 10-NCP (20 mM) (F) in the absence or presence of bafilomycin A1 (200 nM) was calculated from four
independent experiments (n = 4), including an independent neural induction in each case. Error bars, SEM.(Figures 5A–5C). To further investigate the consequences of
accumulation of b-CTF on the lysosomal and autophagy systems
in non-diseased control neurons, we used small molecule inhib-
itors of g-secretase to prevent turnover of b-CTF (Figure 5D).
As expected, inhibition of either g- or b-secretase significantly
reduced extracellular Ab peptides (Figure 5E), and g-secretase
inhibition led to a marked accumulation of b-CTF (Figure 5F).3652 Cell Reports 25, 3647–3660, December 26, 2018Inhibition of g-secretase led to an increase in both LAMP1 pro-
tein and LC3-II levels in healthy control neurons (Figure 5F).
Together with the increase in LAMP1 protein levels, there was
a significant increase in the number of enlarged lysosomes in
neurons following g-secretase inhibition (Figures 5G and 5H).
Furthermore, g-secretase inhibition led to an accumulation
of LC3-positive autophagosomes, with g-secretase inhibition
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Figure 5. Gamma-Secretase Inhibition Disrupts Function of the Lysosomal-Autophagic System in Human Neurons
(A–C) APP-b-CTF levels are significantly increased in human cortical excitatory neurons with APP and PSEN1 mutations (intron 4, Y115C, or M146I), compared
with non-demented controls (two-tailed t test between controls and AD neurons). Representative western blots of FL-APP, APP-bCTF, and neuron-specific
b3-tubulin in three independent control and AD neurons are shown (A). Levels of FL-APP (B) and ratio of bCTF/FL-APP (C) were calculated relative to b3-tubulin
and normalized to non-demented controls (n = 3). Error bars, SEM.
(D) Schematic of APP processing to generate Ab peptides.
(E and F) Multiplexed ELISA (MSD) quantification of extracellular Ab peptides (E) from non-demented control neurons following treatment with BSI shows sig-
nificant reduction in the production of Ab38, Ab40, and Ab42, compared to Ctrl. Similarly, GSI significantly reduces extracellular Ab. Representative western blots
of LAMP1, LC3I/II, APP-CTF, and neuron-specific b3-tubulin are shown (F). Neurons treated from day 65 to day 85 with the indicated compounds at a final
(legend continued on next page)
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markedly increasing the number and size of the GFP-LC3 puncta
in neurons (Figures 5G and 5I). In addition, live imaging of axonal
transport of lysosomes found that lysosome transport was
significantly impaired in neurons following g-secretase inhibition
(Figures 5J–5L). Inhibition of g-secretase led to both an increase
in stationary lysosomes within axons, as well as a reduction in
both retrograde and anterograde lysosome transport (Figures
5J–5L). Furthermore, we observed a significant reduction in the
percentage of lysosomes that contained CatD-positive signals
in healthy control neurons treated with GSI (Figure 5M).
To investigate whether the observed autophagosome accu-
mulation was caused by induction of autophagy or by inhibition
of degradation, we measured autophagic flux as described
above (Figure 4C). In contrast with familial AD neurons,
we found that autophagosome synthesis was increased
following either b-secretase or g-secretase inhibition (Figures
5N and 5O). However, whereas degradation was not changed
following b-secretase inhibition, g-secretase inhibition signifi-
cantly reduced autophagosome degradation (Figure 5P).
These data indicate that reducing g-secretase turnover of
C terminus of APP leads to lysosomal-autophagic dysfunc-
tion, suggesting that the turnover of the C terminus of APP
by g-secretase has a regulatory role in modulating the lyso-
somal-autophagy system.
Dysfunction in the Lysosome-Autophagy System in
Familial AD Neurons Is Reversed by b-Secretase
Inhibition
Given that inhibition of APP-CTF turnover by g-secretase nega-
tively impacted the lysosomal-autophagy system in healthy neu-
rons, we investigated the effect of manipulating APP processing
on lysosome-autophagy defects in AD neurons. We focused on
addressing whether reducing the production of b-CTF by inhibi-
tion of b-secretase would ameliorate autophagy defects in
monogenic AD neurons (PSEN1 and APPmutations, trisomy 21).
As expected, inhibition of b-secretase activity significantly
reduced the production of total APP-bCTF levels (Figure 6A)
and total extracellular Ab peptides in neurons of all genotypesconcentration of 5 mM. Data were calculated from three independent expe
Error bars, SEM.
(G) Live imaging of iPSC-derived neurons expressing LAMP1-RFP (red; blue, nucl
with NucBlue). Scale bar, 10 mm.
(H and I) Significant increases in the size of (H) LAMP1-RFP-positive late endo
demented control neurons treated with GSI (two-tailed t test between DMSO and
measures in (H) or (I) were from three independent experiments, including an ind
(H) (n): 326 (Ctrl), 350 (GSI). Total number of vesicles measured in (I) (n): 90 (Ctrl)
(J) Impaired axonal lysosome transport in non-demented control human neurons
with 100 nM LysoTracker Red DND-99. Scale bar, 10 mm.
(K and L) Significant reduction in lysosome motility (K) and number of stationary ly
(two-tailed t test between DMSO and GSI-treated neurons in each case). Total nu
three independent experiments, with total numbers of axons (n) indicated within
(M) Significant reduction in the percentage of lysosomes that contained CatD
(two-tailed t test between DMSO and GSI-treated neurons in each case). Axons w
(n) indicated within each bar. Error bars, SEM.
(N–P) Autophagosome degradation was significantly reduced in non-demented c
(two-tailed t test between DMSO and GSI-treated neurons). Representative wes
human neurons treated with DMSO, BSI, or GSI are shown (N). Rates of autopha
CCCP (20 mM) in the absence or presence of bafilomycin A1 (200 nM) were c
Error bars, SEM.
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ity alters LAMP1 expression in genetic forms of AD (Figure S5).
In addition, there was a significant reduction in the size of
p62/SQSTM1-positive vesicles in familial AD and trisomy 21
neurons, suggesting that b-secretase inhibition corrected de-
fects in the degradative phase of autophagy (Figures 6C and
6D). Measurements of autophagic flux in monogenic AD neurons
treated with b-secretase inhibitor were performed using the
same methods as described above. As indicated by the imaging
of p62-RFP, b-secretase inhibition led to a significant increase of
the degradation phase of autophagy compared to vehicle-
treated neurons of each genotype (Figures 6E–6G).
Autophagy Defects in PSEN1 Mutant Neurons Are
Rescued by CRISPR Knockout of APP
While the pharmacological manipulation of both BACE1 and
g-secretase strongly implicated APP in mediating PSEN1-
dependent phenotypes, they do not formally prove this. To
investigate this, we used CRISPR genome engineering to
knockout both alleles ofAPP in PSEN1 Y115C iPSCs (Figure 7A).
Cortical neurons generated from two independent clones of
PSEN1 Y115C;APP/ iPSCs had no detectable production of
extracellular Ab peptides (Figures 7B and 7C), confirming the
complete absence of APP.
Deletion of APP in PSEN1 Y115C neurons reduced LAMP1
protein levels (Figure 7C) and increased the axonal transport of
lysosomes (Figures 7D and 7E), compared with isogenic
PSEN1 Y115C neurons. Removal of APP also rescued auto-
phagy defects in PSEN1 Y115C neurons. There was a significant
reduction in the size of p62-RFP positive vesicles in the APP
knockout neurons, compared with isogenic PSEN1 Y115C neu-
rons (Figures 7F and 7G). Measuring autophagic flux in isogenic
PSEN1 Y115C and PSEN1 Y115C;APP/ neurons demon-
strated that removal of APP protein rescued the impairment in
the degradative phase of autophagy seen in PSEN1 Y115C neu-
rons (Figures 7H and 7I). Therefore, these data demonstrate that
the lysosomal-autophagy defects observed in PSEN1 mutant
neurons are APP-dependent.riments (n = 3), including an independent neural induction in each case.
ei labeled with NucBlue) or LC3-GFP fusion protein (green; blue, nuclei labeled
somes and/or lysosomes and (I) LC3-GFP-positive autophagosomes in non-
GSI-treated neurons in each case). LAMP1-RFP+ and LC3-GFP+ vesicle size
ependent neural induction in each case. Total number of vesicles measured in
, 111 (GSI). Error bars, SEM.
treated with GSI, as detected by live imaging of iPSC-derived neuron labeled
sosomal vesicles (L) in non-demented control human neurons treated with GSI
mber of axons measured in (H) (n): 25 (Ctrl), 26 (GSI). Axons were measured in
each bar in (L). Error bars, SEM.
-positive signals in non-demented control human neurons treated with GSI
ere measured in three independent experiments, with total numbers of axons
ontrol human neurons treated with GSI, as detected by western blot analysis
tern blots of LC3I/II and neuron-specific b3-tubulin in non-demented control
gosome (O) synthesis and (P) degradation following autophagy induction with
alculated relative to b3-tubulin from four independent experiments (n = 4).
A B
C
D
E
F G
Figure 6. Dysfunction in the Lysosome-Autophagy System in Familial AD Neurons Is Reversed by b-Secretase Inhibition
(A) BSI reduces APP-bCTF level in all genotypes. Representative western blots of FL-APP, APP-bCTF, and neuron-specific b3-tubulin are shown.
(B) Multiplexed ELISA quantification of extracellular Ab peptides from monogenic AD neurons following treatment with BSI shows significant reduction in the
production of total Ab peptides, compared to controls (two-tailed t test between DMSO and BSI-treated neurons in each case). Neurons treated between from
day 65 to day 85 with BSI at a final concentration of 5 mM. Data were calculated from three independent experiments (n = 3), including an independent neural
induction in each case. Error bars, SEM.
(C) Live imaging of iPSC-derived neurons co-expressing p62-RFP (red) and LC3-GFP (green) fusion proteins (blue, nuclei labeled with NucBlue). Scale bar, 10 mm.
(D) Significant reductions in the size of p62-RFP-positive autophagosomes in monogenic AD neurons treated with BSI, compared with DMSO-treated controls
(two-tailed t test between DMSO and BSI-treated neurons in each case). p62-RFP+ vesicle size measures in (C) were from three independent experiments,
including an independent neural induction in each case. Total number of vesicles measured (n): 558 (APP V717I Ctrl), 396 (APP V717I BSI), 479 (APPdup(1) Ctrl),
484 (APPdup(1) BSI), 574 (APPdup(2) Ctrl), 541 (APPdup(2) BSI), 384 (Ts21 Ctrl), 399 (Ts21 BSI), 628 (PSEN1 Y115C Ctrl), 614 (PSEN1 Y115C BSI), 240
(PSEN1 M146I Ctrl), and 291 (PSEN1 M146I BSI). Error bars, SEM.
(E) Representative western blots of LC3I/II and neuron-specific b3-tubulin in familial AD neurons treated with DMSO or BSI are shown.
(F and G) Schematic of the autophagy flux assays (F) used for this set of comparisons (E). Autophagosome degradation (basal level) was calculated by comparing
LC3-II levels following treatment with CCCP in the presence (lane 4) or absence (lane 3) of bafilomycin A1 (i.e., lane 4 versus lane 3). Similarly, autophagosome
degradation (treatedwith BSI) was calculated by comparing LC3-II levels following treatment with CCCP in the presence (lane 5) or absence (lane 6) of bafilomycin
A1 (i.e., lane 5 versus lane 6).
(G) LC3-II levels were calculated relative to b3-tubulin from three independent experiments (n = 3) (two-tailed t test between DMSO and BSI-treated neurons in
each case). Error bars, SEM.
See also Figure S5.
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Figure 7. Autophagy Defects in PSEN1 Mutant Neurons Are Rescued by CRISPR Knockout of APP
(A) Double nickase strategy with sense (S) and antisense (AS) single guide RNAs (sgRNAs) separated by 9 bp at exon 3 of the APP locus on chromosome 21.
Red arrows indicate the cut sites of Cas9D10A nickase, which generates 50 overhangs at target sites.
(B) CRISPR targeting of both alleles of APPwas confirmed by the complete absence of extracellular Ab peptides generated by PSEN1 Y115C;APP knockout (KO)
neurons, compared with isogenic PSEN1 Y115C neurons. Multiplexed ELISA quantification of extracellular Ab peptides from unedited and two independent
clones of APP KO neurons from three independent experiments (n = 3).
(C) APP protein was not detected in two independent clones of PSEN1 Y115C; APP KO neurons, confirming complete knockout of both APP alleles. In contrast,
total LAMP1 levels are decreased in two independent clones of PSEN1 Y115C;APP KO neurons (90 days post-neural induction), compared with unedited PSEN1
Y115C neurons (two-tailed t test between unedited and KO neurons). Representative western blots of APP, LAMP1, b-actin, and neuron-specific b3-tubulin
unedited isogenic PSEN1 Y115C and two independent clones of PSEN1 Y115C;APP KO neurons.
(D and E) Live imaging of iPSC-derived neurons labeled with 100 nM LysoTracker Red DND-99 (D). Scale bar, 10 mm. Significant increases in the number of
moving lysosomal vesicles (E) in two independent clones ofPSEN1Y115C;APPKO neurons, comparedwith unedited isogenicPSEN1Y115C neurons (two-tailed
(legend continued on next page)
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DISCUSSION
We report here that mutations in APP and PSEN1 that are causal
for early onset AD lead to major defects in lysosome function
and autophagy in human neurons. The rapid appearance of
these defects indicates that they are a direct effect of those mu-
tations, and not a secondary consequence of a primary degen-
erative process, such as protein aggregation. Consistent with
this, we find that inhibition of g-secretase causes lysosomal
and autophagy dysfunction in healthy human neurons. APP
and PSEN1 mutant neurons accumulate APP-b-CTF and
reducing production of C-terminal APP by inhibition of BACE1
rescued lysosome-autophagy phenotypes in both APP and
PSEN1mutant neurons. Defects in the lysosome and autophagy
systems due to PSEN1 mutations are prevented by CRISPR
knockout of APP, demonstrating that lysosome and autophagy
dysfunction in PSEN1 mutant neurons are dependent on the
presence of APP. These data demonstrate that compromised
proteolysis of the C-terminal of APP by g-secretase by auto-
somal dominant mutations in PSEN1 and APP causes dysfunc-
tion of the lysosomal and autophagy systems in human neurons
and represents a potential driver of neurodegeneration in mono-
genic AD.
We and others have previously reported that neurons gener-
ated from iPSCs with genetic forms of AD recapitulate aspects
of the disease, including increased Ab peptide production in
trisomy 21 and APP duplication neurons (Moore et al., 2015;
Israel et al., 2012) and increased production of longer forms of
Ab in PSEN1 and APP mutant neurons (Moore et al., 2015;
Muratore et al., 2014; Woodruff et al., 2016; Israel et al., 2012).
We now report that AD mutations in APP and PSEN1 converge
on disruption of the lysosome and autophagy system in human
neurons. Given growing evidence from genome-wide associa-
tion studies implicating the endolysosomal and autophagy sys-
tems in AD risk (Karch and Goate, 2015), these data suggest
that dysfunction in these systems may represent an early patho-
genic process in the disease.
The contributions of the endolysosomal and autophagy sys-
tems to AD initiation and progression are currently unclear,
with debate surrounding whether observed defects in those sys-
tems are causes or consequences of neuronal dysfunction and
neurodegeneration (Nixon, 2017). Post-mortem analyses of the
cerebral cortex have demonstrated enlarged early endosomes
in neurons of individuals with trisomy 21 or APP duplication
(Cataldo et al., 2000), as well as in transgenic mouse models
expressing human APP, trisomy 21 fibroblasts, and various cell
lines overexpressing different forms of APP (Nixon, 2017). Focalt test between unedited and KO neurons). Axons were measured in three indepe
Error bars, SEM.
(F and G) Significant decreases in the size of p62-RFP-positive autophagosomes
with unedited isogenic neurons (two-tailed t test between unedited and KO neur
experiments, including an independent neural induction in each case. Total nu
Y115C;APP KO Clone 1), and 602 (PSEN1 Y115C;APP KO Clone 2). Error bars,
(H and I) Impaired autophagosome degradation was significantly rescued in two in
isogenic neurons (two-tailed t test between unedited and KOneurons). Represent
clones of PSEN1 Y115C;APP KO neurons are shown (H).
(I) LC3-II levels following autophagy induction with 10-NCP (20 mM) in the absenc
from three independent experiments (n = 3). Error bars, SEM.axonal swellings containing accumulations of lysosomal dense
bodies and autophagic vacuoles have been observed in post-
mortem brain samples of Alzheimer’s patients (Nixon, 2013,
2017; Nixon et al., 2005), suggesting a failure of their axonal
transport.
We have found that mutations in APP and PSEN1 converge on
defects in lysosome function and autophagy. The presence of
these changes within relatively young neurons, combined with
the ability to induce these phenotypes by acute gamma-
secretase inhibition, indicates that these defects are a direct
consequence of mutations in APP and PSEN1, and not an indi-
rect effect of another degenerative process, such as protein
aggregation. PSEN1 mutant neurons do not have early endo-
some defects, in contrast with APP mutant neurons. This is
consistent with previous analysis from post-mortem studies
showing that early endosomal abnormalities were not found in
individuals with either PSEN1 or PSEN2 mutations, despite Ab
overproduction and amyloid plaque deposition (Cataldo et al.,
2000). In addition, endosomal dysfunction was also absent in
both primary fibroblasts from patients with PSEN1 mutation
and neurons from PS1 and bAPP transgenic mice (Cataldo
et al., 2000). Our finding that the different APP and PSEN1muta-
tions overlap in lysosome and autophagosome dysfunction sug-
gest that the primary site of action of thesemutant proteins is the
lysosome, with endosomal changes being a secondary effect.
Processing of APP by BACE1 in the endosome generates the
APP C-terminal fragment (APP-b–CTF), which is in turn a sub-
strate for g-secretase in the lysosome. The role of APP-CTF in
AD pathogenesis is the subject of considerable debate. Previous
studies have suggested that intraneuronal accumulation of APP-
CTF is a consequence of impaired lysosomal-autophagic degra-
dation, rather than a cause of endolysosome or autophagy
dysfunction (Peric and Annaert, 2015). In addition, a recent study
showed that deletion of APP expression in mice deficient for all
g-secretases, by deletion of the genes encoding Aph1 subunits,
failed to rescue progressive neurodegeneration (Acx et al.,
2017). In that case, there was a general accumulation of many
g-secretase substrates, due to complete loss of g-secretase
function, which is in contrast to the hypomorphic character of
autosomal dominant pathogenic mutations in PSEN1 (Moore
et al., 2015; Cha´vez-Gutie´rrez et al., 2012). Recent studies,
however, have reported that intraneuronal aggregation of
APP-CTF induced Ab-independent lysosomal-autophagic
pathology (Lauritzen et al., 2016; Jiang et al., 2016). We found
that increasing intracellular APP-CTF by g-secretase inhibition
induced lysosomal-autophagic pathology: elevated levels of
lysosomal LAMP1 and autophagosome LC3-II, increasedndent experiments, with total numbers of axons (n) indicated within each bar.
(F) in two independent clones of PSEN1 Y115C;APP KO neurons, compared
ons) (G). p62-RFP+ vesicle size measures in (G) were from three independent
mber of vesicles measured (n): 799 (Unedited;PSEN1 Y115C), 840 (PSEN1
SEM.
dependent clones ofPSEN1 Y115C;APPKO neurons, comparedwith unedited
ative western blots of LC3I/II and neuron-specific b3-tubulin in two independent
e or presence of bafilomycin A1 (200 nM) were calculated relative to b3-tubulin
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density and size of LC3-positive puncta, and increased number
of enlarged LAMP1-positive vesicles. In addition, g-secretase in-
hibition markedly impaired axonal transport of lysosomes and
led to autophagic defects.
Conversely, we find that dysfunction in lysosomal-autophagy
system observed in human APP and PSEN1 mutant neurons
canbe reversed by b-secretase inhibition, which reduces the sup-
ply of APP-b-CTF to the late endosome and/or lysosome (Jiang
et al., 2010). These data argue that accumulation and/or altered
turnover of APP-CTF by g-secretase lead to dysfunction in the
neuronal lysosomal-autophagy system. Importantly, the rescue
of lysosomal-autophagy defects by CRISPR deletion of APP in
a PSEN1 mutant background formally demonstrates that those
defects are dependent on APP protein, and not simply conver-
gent independent phenotypes due to mutations in either gene.
The lack of detectable defects in lysosome and autophago-
some function in PSEN1 Intron4 neurons is surprising, given
that these neurons have similar changes in Ab peptide produc-
tion as the other PSEN1 mutant neurons. However, the molecu-
lar nature of the PSEN1 Intron4mutation is qualitatively different
from the majority of PSEN1 mutations, which are missense
protein-coding mutations that result in single amino acid substi-
tutions (De Jonghe et al., 1999). The PSEN1 Intron4 mutation is
a single base deletion within the splice donor site, which has
been predicted to generate three different final mRNAs, two of
which encode truncated forms of PSEN1, and the third includes
an extra amino acid (De Jonghe et al., 1999). If this is the case in
cortical neurons, the relative amounts of wild-type and full-length
mutant PSEN1 proteins would be much less than 1:1, and
relatively higher levels of the wild-type form of PSEN1 might
enable short-term compensation for the deleterious effects of
the mutant protein. Therefore, it will be essential to further study
the effects of this mutation on lysosome and autophagosome
function over longer time frames and in neurons homozygous
for this mutation.
The early stage of axonal lysosome biogenesis is thought to
begin in distal regions of axons with the merging of organelles
derived from endocytic and autophagic pathways (Maday and
Holzbaur, 2014). Further maturation of lysosomes requires retro-
grade transport to the cell soma where luminal proteases can be
delivered from the trans-Golgi network efficiently (Maday et al.,
2012). Such a mechanism allows neurons to effectively remove
autophagic cargos from axon terminals and synapses. We found
that AD mutations in APP and PSEN1 markedly disrupted the
axonal transport of lysosomes and those lysosomes accumulate
within distal axons contained low levels of cathepsin D. This is
similar to previous findings in human AD brain tissue as well as
various AD mouse models in which focal axonal swellings
containing accumulations of lysosomal dense bodies and
autophagic vacuoles have been observed (Nixon, 2017).
Although autophagy activation may be a promising therapeu-
tic strategy for AD, its beneficial role in disease pathogenesis is
not clear. Several studies showed that increasing autophagy in
mousemodels of AD ameliorates amyloid pathologies andmem-
ory deficits (Spilman et al., 2010; Yang et al., 2011). However,
autophagy induction has also been reported to activate the amy-
loidogenic pathway and increase Ab secretion (Yu et al., 2005;
Nilsson et al., 2013). Similarly, administration of rapamycin after3658 Cell Reports 25, 3647–3660, December 26, 2018the formation of amyloid plaques failed to rescue the cognitive
deficits in mouse model of AD (Majumder et al., 2011). Our
data suggest that induction of autophagy may become counter-
productive in the face of impaired transport of axonal lysosomes,
lysosomal clearance deficits and reduced autophagosome
degradation, by further overburdening the already failing lyso-
somes and thus exacerbating autophagic accumulation in
axons. Indeed, recent studies have demonstrated that restoring
retrograde transport of autophagic vacuoles by overexpressing
Sanpin proteins successfully reduced AD-associated autopha-
gic stress (Tammineni et al., 2017). The present study on human
cortical neurons provides further evidence that either reducing
input of APP to the lysosomal-autophagy system, enhancing
axonal transport or augmenting lysosome function at the early
disease stages may represent potential therapeutic strategies
to attenuate autophagic defects in AD. Overall, this study estab-
lishes a foundation for future investigation into cellular pathways
enhancing autophagy and lysosomal proteolytic activity as an
approach to ameliorating neurodegeneration in AD.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human iPSC lines
Non-demented control iPSC lines: Non-Demented-Control (NDC) (Israel et al., 2012), SFC840 (StemBANCC), and AD3.1
(StemBANCC). All AD lines were previously reported and characterized: PSEN1 Y115C, M146I, intron 4, and APP V717I iPSCs
(Moore et al., 2015); APP duplication (Israel et al., 2012; Moore et al., 2015) and Ts21 iPSCs (Park et al., 2008; Moore et al., 2015;
Shi et al., 2012b). This research was carried out in accordance with the UK Code of Practice for the Use of Human Stem Cell Lines.
METHOD DETAILS
Directed differentiation to human cortical neuron culture
Directed differentiation of iPSCs to cerebral cortex was carried out as described (Moore et al., 2015). Briefly, dissociated iPSCs were
plated on GelTrex-coated 6-well plates and neural induction were initiated by changing into culture medium that supports neuronal
differentiation and neurogenesis, a 1:1 mixture of N2- and B27-containing media (supplemented with dorsomorphin and SB431542
to inhibit TGF b signaling during neural induction). Neuroepithelial cells were harvested with dispase and replated in laminin-coated
plates with FGF2-containing media. FGF2 was withdrew for 4 days to promote differentiation, passaged with accutase, and main-
tained for up to 120 days with a medium change every other day. To establish identity and quality of cortical neuronal inductions,
gene expression profiling was performed on a custom gene expression panel. RNA was isolated from induced cortical neurons,Cell Reports 25, 3647–3660.e1–e2, December 26, 2018 e1
85 – 90 days after induction, using an RNA extraction kit (QIAGEN), according to themanufacturer’s instructions. Expression levels of
mRNAs enriched in deep and upper layer cortical neurons were assessed on the Nanostring nCounter platform (Figure S1).
For drug treatments, all compounds were dissolved in DMSO at the concentrations specified, and DMSO was used as vehicle
control in all experiments. Compounds were added every 48 hr during treatment period: b-secretase inhibitor OM99-2 (Calbiochem);
and g-secretase inhibitor, DAPT (Sigma).
Protein analysis
Extracellular Ab 1-42, Ab 1-40, and Ab 1-38 were measured in conditioned media using multiplexed MesoScale Discovery assays
on a Quickplex SQ120 instrument (MesoScale Discovery). All statistical analysis was performed between the entire set of controls
samples and all samples of each genotype, using Student’s t test with the Bonferroni correction for multiple testing.
Immunoblotting
For immunoblotting, whole cell lysate protein was extracted with RIPA buffer (Sigma). Samples were separated on a 4%–12%
SDS-PAGE and transferred to PVDF membranes. Proteins were detected (Li-Cor Odyssey system) by incubation with specific
primary antibodies and appropriate secondary antibodies. Antibodies used in this study are listed in Key Resources Table.
Live cell imaging and confocal microscopy
For live cell imaging, Rab5A-GFP (Catalog no. C10586), LAMP1-RFP (Catalog no. C10597), LC3-GFP (Catalog no. P36235) and
p62-RFP (Catalog no. P36241) were expressed in day 80-85 neurons using commercial viral vectors (ThermoFisher Scientific).
Neurons were transferred into live-imaging solution (Invitrogen) 16 hours after infection in order to improve imaging of fluorescent
proteins. Cells were viable and appearedmorphologically normal in imagingmedium for at least 24 hours. As an alternative to expres-
sion of LAMP1-RFP, neuronal lysosomes were visualized by incubation of 100 nM LysoTracker Red DND-99 (Molecular Probes) with
or without the addition of Pepstatin A, BODIPY FL Conjugate (Invitrogen) in fresh medium for 30 minutes at 37C. Neurons were
washed and then replaced with fresh culture medium before imaging. For imaging axonal transport of lysosomes, neurons were
cultured in microfluidic devices (XONA microfluidics) mounted onto glass coverslips coated with Geltrex (Life Technologies).
Time-lapse images were acquired using a Zeiss SP5 confocal microscope. Cultures weremaintained at 37C in a CO2 environment
chamber. Time-lapse images were acquired in a single focal plane at 2 s intervals for 60 stacks. Data were collected in the axon, up to
approximately 900 microns away from the cell body (assuming the cell body is located at the opening of the micro-channel). For the
analysis of vesicle size of fluorescently labeled particles, the imagewas first pre-processed to reduce noise and the coordinates were
calculated using differences of Gaussian, and then single particle was tracked with TrackMate plugin (Tinevez et al., 2017). ImageJ
was used for generation of kymograph and analysis of particle motility as described previously (Hung and Coleman, 2016).
For immunostaining, cells were fixed in 4%paraformaldehyde (PFA) in PBS followed by permeabilization with Triton X-100 (Sigma).
Fixed cells were blocked with 50% normal donkey serum (Sigma) in PBS, probed with primary antibodies diluted in blocking solution
(antibodies listed in Key Resources Table) and detected with goat anti-mouse, anti-chicken or anti-rabbit secondary antibody
coupled to Alexa Fluor 488 or 594. Confocal images were acquired using a Zeiss SP5 confocal microscope.
CRISPR-mediated gene knockout
The following sites were used for designing the optimal sgRNA pairs for nickase targeting and prediction of off-target sites: CRISPR
Design (http://zlab.bio/guide-design-resources) and WTSI Genome Editing (https://www.sanger.ac.uk/htgt/wge/). The All-in-One
nickase vector plasmid (gift from Prof S Jackson, Cambridge) (Chiang et al., 2016). Pairs of complementary DNA oligos were
purchased in standard desalted format from IDT:
sgRNA-sense (S): 50 ATCCAGAACTGGTGCAAGCGGGG 30
sgRNA-antisense (AS): 50 TTGGTTGGCTTCTACCACATTGG 30
Both sense and antisense sgRNA oligos were cloned into the All-in-One nickase vector and the correct sequence was verified by
Sanger sequencing. Plasmids were transfected into iPSCs by electroporation using the Neon Transfection System according to the
manufacturer’s instructions (Life Technologies). Cells were trypsinised 48 hours after transfection, washed with Essential 8 medium
(Thermo Fisher), and sorted based on EGFP signal into Geltrex (Life Technologies)-coated 10 cm2 dish (Thermo Scientific) at a low
density and individual colonies were picked manually for clonal expansion.
QUANTIFICATION AND STATISTICAL ANALYSIS
Unless otherwise specified, statistics analysis was performed using GraphPad Prism (Version 7). Unpaired Student’s t test was used
to compare differences between two groups, assuming the data were normally distributed. One-way ANOVA with a post hoc Tukey
test was used to analysis differences betweenmore than two groups (i.e., genotypes). For precise p value calculation, amultiple t test
was performed after ANOVA calculations. Significance threshold was defined as adjusted p value < 0.05. Error bars in all figures
represent SEM. The number of biological replicates (n) is listed in the legend of each figure.e2 Cell Reports 25, 3647–3660.e1–e2, December 26, 2018
